{"id":576439,"date":"2021-03-04T00:00:00","date_gmt":"2021-03-04T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnecg0010-2021-biopharma-epilepsy-unmet-need-dravet-syndrome-us-eu-2021\/"},"modified":"2026-03-31T10:43:48","modified_gmt":"2026-03-31T10:43:48","slug":"unnecg0010-2021-biopharma-epilepsy-unmet-need-dravet-syndrome-us-eu-2021","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnecg0010-2021-biopharma-epilepsy-unmet-need-dravet-syndrome-us-eu-2021\/","title":{"rendered":"Epilepsy | Unmet Need | Dravet Syndrome | US\/EU | 2021"},"content":{"rendered":"<p>Dravet syndrome (DS) is a rare, severe, pediatric-onset form of epilepsy characterized by developmental delay or regression and multiple types of difficult-to-treat seizures. Only a handful of antiepileptic drugs (AEDs), including Diacomit (stiripentol), Epidiolex \/ Epidyolex (cannabidiol), and Fintepla (fenfluramine), are approved for the adjunctive treatment of DS, but owing to various factors, off-label generic AEDs such as clobazam and valproate remain the first-line choice in DS treatment. Moreover, most patients do not achieve complete seizure control with currently available AEDs, even when prescribed concomitantly. Understanding the drivers of clinical decision-making in DS, prescribers\u2019 perception of current treatment options, and areas of remaining unmet need will help drug developers identify levers to optimize the positioning and differentiation of new products.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What are the treatment drivers and goals for DS?<\/li>\n<li>What attributes drive decision-making in DS, which have limited impact, and which are hidden opportunities?<\/li>\n<li>How do approved agents (i.e., Diacomit, Epidiolex \/ Epidyolex, and Fintepla) perform on these attributes? How do key off-label AEDs (i.e., clobazam, topiramate, and valproate) perform on these attributes?<\/li>\n<li>What are the prevailing areas of unmet need and opportunity in DS?<\/li>\n<li>Based on a conjoint analysis and TPP simulation, what trade-offs across different clinical attributes and price are acceptable to neurologists for a hypothetical new DS drug?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.<\/p>\n<p><strong>Markets covered:<\/strong> United States, United Kingdom, France, Germany<\/p>\n<p><strong>Primary research: <\/strong>Survey of 60 U.S. and 31 European neurologists fielded in January 2021<\/p>\n<p><strong>Key companies:<\/strong> Biocodex, GW Pharmaceuticals, Zogenix, Takeda, Zynerba Pharmaceuticals<\/p>\n<p><strong>Key drugs:<\/strong> Diacomit, Epidiolex \/ Epidyolex, Fintepla, clobazam, topiramate, valproate<\/p>\n","protected":false},"template":"","class_list":["post-576439","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-epilepsy","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/576439","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/576439\/revisions"}],"predecessor-version":[{"id":577579,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/576439\/revisions\/577579"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=576439"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}